Spruce Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript
Welcome back everyone to the 2023 RBC Global Healthcare Conference. My name is Greg Renza, one of the senior biotechnology equity research analysts here at RBC. And we're pleased to be joined now by Spruce Biosciences and representing the company is the Chief Executive Officer, Javier Szwarcberg.
Javier, it's great to see you. I think the best way to kick this off is the pitch it over to you just to give an introduction and brief intro on Spruce.
Perfect, Greg. Thank you so much. Thank you, RBC, and thank you for having me here today.
So Spruce is a biotechnology company focused on developing compounds for rare endocrine disorders. We're currently focusing primarily on CAH, which stands for congenital adrenal hyperplasia. It is a disease for which there is a significant unmet need, a disease for which not only compounds have actually been -- actually there's no approved compound and there's not a lot of research going on at the moment. Overall
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |